Colleen Sweeney, co-director of the UC Davis Cancer Center Breast Cancer Research Program, has found that the gene MET reduces the effectiveness in some patients of the popular breast-cancer drug trastuzumab, commonly referred to by the brand name Herceptin. The study, published in Cancer Research, indicates that the MET gene should be a target for future drug studies.